Maraviroc: a guide to its use in HIV-1 infection
Adapted from Drugs 2007; 67 (15): 2277–88
What is the rationale for developing the drug?
Although much progress has been made in the treatment of HIV-1 infection, there is an ongoing need for new classes of antiretroviral agents. It has been known for >20 years that the CD4 receptor on T cells and macrophages is the main receptor utilized by HIV-1 for entry into the host cell. More recently, the chemokine receptors CCR5 and CXCR4 were identified as essential coreceptors for HIV-1 entry. Generally, only viral strains that utilize the CCR5 coreceptor for entry (R5-tropic HIV-1 virus) are detected during early HIV-1 infection, whereas X4-tropic viruses, which utilize the CXCR4 coreceptor for host cell entry, tend to develop later on in infection in ≈50% of patients and often herald the onset of AIDS.
The development of antiretroviral therapy utilizing CCR5 antagonism has been of particular interest since genetic evidence of a naturally resistant human population came to light....
KeywordsMaraviroc Enfuvirtide Delavirdine Tipranavir CCR5 Antagonist
- 2.Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005 Nov; 49(11): 4721–32PubMedCrossRefGoogle Scholar
- 3.European Medicines Agency. Celsentri: summary of product characteristics [online]. Available from URL: http://emea.europa.eu [Accessed 2007 Dec 7]
- 4.Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006 May; 80(10): 4909–20PubMedCrossRefGoogle Scholar
- 5.Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results from a phase 2b/3 study in the US and Canada [abstract no. 104bLB plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)Google Scholar
- 6.Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24-week results [abstract no. 104aLB plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)Google Scholar
- 7.Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase 3 studies MOTIVATE 1 and MOTIVATE 2 originates from a pre-existing minority of CXCR4-using virus [abstract no. 56 plus poster and oral presentation]. XVI International HIV Drug Resistance Workshop; 2007 Jun 12–16; BarbadosGoogle Scholar
- 9.Selzentry™ (maraviroc tablets): US prescribing information. New York: Pfizer Inc., 2007 AugGoogle Scholar
- 10.Lalezari J, Mayer H. Efficacy and safety of maraviroc in antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1 [abstract no. H-718a]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)Google Scholar
- 11.Proestel S. FDA analyses of maraviroc safety data [online]. Available from URL: http://www.fda.gov [Accessed 2007 Jul 23]
- 12.FDA Maraviroc Review Team. FDA cover memorandum [online]. Available from URL: http://www.fda.gov [Accessed 2007 Apr 25]